These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 21369645)
1. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors. Chen M; Holland MJ; Mir MR; Wong MG; Kelley BP; Grim KD; Bhuchar SS; Hsu S J Drugs Dermatol; 2011 Mar; 10(3):280-4. PubMed ID: 21369645 [TBL] [Abstract][Full Text] [Related]
2. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008 [TBL] [Abstract][Full Text] [Related]
3. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab. Mössner R; Reich K Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553 [TBL] [Abstract][Full Text] [Related]
4. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Gniadecki R; Kragballe K; Dam TN; Skov L Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290 [TBL] [Abstract][Full Text] [Related]
5. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634 [TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517 [TBL] [Abstract][Full Text] [Related]
7. [Biological treatment of psoriasis and psoriatic arthritis]. Kragballe K; Deleuran B Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300 [TBL] [Abstract][Full Text] [Related]
8. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature. Montesu MA; Addis GM; Satta R; Cottoni F G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393 [TBL] [Abstract][Full Text] [Related]
9. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. Weinberg JM; Bottino CJ; Lindholm J; Buchholz R J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412 [TBL] [Abstract][Full Text] [Related]
10. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748 [TBL] [Abstract][Full Text] [Related]
11. Anti-TNF agents for the treatment of psoriasis. Kircik LH; Del Rosso JQ J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380 [TBL] [Abstract][Full Text] [Related]
13. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients. Brunasso AM; Puntoni M; Salvini C; Delfino C; Curcic P; Gulia A; Massone C Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813 [TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839 [TBL] [Abstract][Full Text] [Related]
15. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543 [TBL] [Abstract][Full Text] [Related]
16. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. Van L; Modi SV; Yang DJ; Hsu S Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778 [No Abstract] [Full Text] [Related]
17. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Tan E; Baker C; Foley P Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178 [TBL] [Abstract][Full Text] [Related]